Background: Hematopoietic stem cell transplantation (HSCT) is a common and effective treatment for multiple malignant and non-malignant pediatric conditions. Graft-versus-host disease (GVHD) is a common complication of HSCT that can be prevented with prophylactic use of calcineurin inhibitor (CNI) immunosuppressants. A complication of HSCT and CNI use is pericardial effusion (PEF), which is frequently treated by CNI discontinuation with or without surgical intervention. No studies to date have evaluated the management of PEF without CNI discontinuation as a means of preventing GVHD flares.
Methods: In this single-center retrospective study, we reviewed the management of PEF in pediatric patients post-HSCT who received conservative or surgical intervention with or without CNI discontinuation between May 2012 and June 2022.
Results: Of the patients found to have PEF, all were given tacrolimus for GVHD prophylaxis. Management of PEF included surgical intervention for 83% of patients, and CNI was not discontinued for 83%. None of the patients developed GVHD during the management of PEF.
Conclusions: Our results demonstrate that continuation of CNI therapy for GVHD prophylaxis did not negatively impact the disease course of PEF in post-HSCT patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/petr.14672 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy analysis of rituximab in treating patients with primary membranous nephropathy dependent on calcineurin inhibitors.
Front Immunol
January 2025
Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Article Synopsis
- This study tested rituximab (RTX) on patients with primary membranous nephropathy (PMN) who were dependent on calmodulin inhibitors (CNIs) and not fully in remission.
- Among 36 patients, those who were drug-dependent showed a significant reduction in proteinuria and improved remission rates after 12 months of RTX therapy, with complete remission increasing from 10% to 70%.
- The results indicated that RTX not only helped patients overcome CNI dependency but also led to significant immunological improvements while minimizing the risks of adverse effects.
Calcineurin-Inhibitor Discontinuation Could Reduce the Risk of De Novo Malignancies After Liver Transplantation for Alcohol-Related Liver Disease.
Clin Transplant
October 2024
Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Background: De novo malignancies are one of the leading causes of death after liver transplantation (LT), particularly in patients transplanted for alcohol-related liver disease (ALD). This retrospective study aimed to assess risk factors for malignancies and to evaluate the impact of calcineurin inhibitor (CNI) discontinuation.
Methods: From 1990 to 2015, all patients transplanted for ALD were included.
Everolimus-Associated Thrombotic Microangiopathy Following Renal Transplant: A Case Report.
Cureus
October 2024
Nephrology, Hospital Pulau Pinang, George Town, MYS.
Thrombotic microangiopathy (TMA) is a serious complication that may affect post-renal transplant recipients. De novo TMA has been linked to the use of transplant immunosuppressive agents, including calcineurin inhibitors (CNI) and mammalian target of rapamycin inhibitors (mTORi). We report a case of a 41-year-old female renal transplant recipient who presented with hemolytic anemia, thrombocytopenia, and acute allograft dysfunction.
View Article and Find Full Text PDFObinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy.
Nephrol Dial Transplant
October 2024
Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Article Synopsis
- Rituximab is effective for treating primary membranous nephropathy but has limited response rates; obinutuzumab, a stronger B-cell depleting antibody, may show better outcomes.
- A study at Huashan Hospital compared the effectiveness of obinutuzumab and rituximab in adult patients resistant to traditional treatments from 2015 to 2024, focusing on overall remission and safety.
- Results revealed a much higher response rate for obinutuzumab (90%) compared to rituximab (38.7%), along with better immunological remission rates, while both treatments had similar safety profiles.
Calcineurin inhibitors-related posterior reversible encephalopathy syndrome in liver transplant recipients: Three case reports and review of literature.
World J Hepatol
September 2024
Department of Intensive Care Unit, Fudan University Affiliated Zhongshan Hospital, Shanghai 200032, China.
Article Synopsis
- Posterior reversible encephalopathy syndrome (PRES) is a serious condition often linked to neurotoxicity from calcineurin inhibitors (CNI), leading to urgent neurological issues and needs for quick diagnosis and intervention.
- The report discusses three liver transplant patients who developed PRES, all of whom improved after changing their CNI treatment and receiving supportive care, showcasing the impact of timely medical responses.
- Early recognition and management of CNI-related PRES are crucial for better outcomes, demonstrating the need for careful monitoring in transplant recipients experiencing acute neurological symptoms.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!